Session » Infection-related Rheumatic Disease Poster (1530–1564)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1560

A Multidisciplinary Timely Approach to Initiate Immunosuppressive Biologic Therapy and Improve COVID-19 Cytokine Storm Syndrome Outcome

8:30AM-10:30AM: Abstract Number: 1536

Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Among Patients with Rheumatic Disease

8:30AM-10:30AM: Abstract Number: 1538

Adverse Events After SARS-CoV-2 Vaccination Among Rheumatology Outpatients in New York City

8:30AM-10:30AM: Abstract Number: 1540

Antibody Response After SARS-CoV-2 Infection in Patients with Rheumatic Diseases: A Multicenter, Nationwide Study

8:30AM-10:30AM: Abstract Number: 1562

B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab

8:30AM-10:30AM: Abstract Number: 1563

Clinical Characteristics and Management of Olecranon and Prepatellar Septic Bursitis in a Multicenter Study

8:30AM-10:30AM: Abstract Number: 1544

Clinical Course and Risk Factors for Severe/Critical COVID-19 in Patients with Rheumatic Diseases – a Multicenter, Nationwide Study

8:30AM-10:30AM: Abstract Number: 1555

Clinical Outcomes of Coronavirus Disease-2019 (COVID-19) in Hospitalized Patients with Rheumatic and Musculoskeletal Diseases (RMD)

8:30AM-10:30AM: Abstract Number: 1533

Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis

8:30AM-10:30AM: Abstract Number: 1554

COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases

8:30AM-10:30AM: Abstract Number: 1542

Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?

8:30AM-10:30AM: Abstract Number: 1543

Epidemiology and Disease Burden of Hospitalized Children with Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 Infection in Canada: A Canadian Pediatric Surveillance Program National Prospective Study

8:30AM-10:30AM: Abstract Number: 1530

Evaluation of the Possible Different Evolution of SARS-CoV-2 Infection with Tumor Necrosis Factor Inhibitors or with Rituximab in Rheumatic Patients

8:30AM-10:30AM: Abstract Number: 1549

Experience from a Diverse Rheumatology Cohort with COVID-19: Are We Doing Better Than We Expected?

8:30AM-10:30AM: Abstract Number: 1550

Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases

8:30AM-10:30AM: Abstract Number: 1551

Generation of Autoantibodies and Their Association with Rheumatic Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Adult Population Following BNT162b2 mRNA Covid-19 Vaccination

8:30AM-10:30AM: Abstract Number: 1539

High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients

8:30AM-10:30AM: Abstract Number: 1546

Immune Responses to COVID-19 Vaccines in Patients Using Immunosuppressive Medication for Inflammatory Arthritis – An Observational Study of 1500 Patients

8:30AM-10:30AM: Abstract Number: 1557

Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases

8:30AM-10:30AM: Abstract Number: 1537

Impact of COVID-19 Infection on Patient-Reported Outcomes in Rheumatic Disease Patients: A Cross Sectional Study

8:30AM-10:30AM: Abstract Number: 1535

Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination

8:30AM-10:30AM: Abstract Number: 1553

Low-dose Tocilizumab in the Treatment of COVID-19 Pneumonitis: 90-day Mortality Follow-up

8:30AM-10:30AM: Abstract Number: 1532

Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease

8:30AM-10:30AM: Abstract Number: 1556

Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)

8:30AM-10:30AM: Abstract Number: 1564

Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study

8:30AM-10:30AM: Abstract Number: 1531

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19

8:30AM-10:30AM: Abstract Number: 1547

Potential Predictors of Outcome for Anakinra Treatment in COVID-19 Patients with Macrophage Activation Syndrome

8:30AM-10:30AM: Abstract Number: 1559

Potential Predictors of Requirement for Mechanical Ventilation in Cases of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C): Results of a Hospital-based Cohort Study from South India

8:30AM-10:30AM: Abstract Number: 1541

Preliminary Criteria for Macrophage Activation Syndrome Associated with Coronavirus Disease-19

8:30AM-10:30AM: Abstract Number: 1561

Prevalence of SARS-CoV2 Infection in Diseases Inflammatory Rheumatology in the Rheumatology Service of the Hospital Docente Padre Billini, Dominican Republic

8:30AM-10:30AM: Abstract Number: 1548

Q Fever as a Mimicker of Rheumatologic Conditions: A Case Series from Two Tertiary Care Academic Centers in Southern California

8:30AM-10:30AM: Abstract Number: 1545

Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor

8:30AM-10:30AM: Abstract Number: 1534

Severity Factors of Covid-19 Infection in Rheumatic Immune-mediated Inflammatory Diseases: Study in a Single University Hospital

8:30AM-10:30AM: Abstract Number: 1552

Systemic Autoimmune Conditions and Hospital Admissions in Covid-19 Infection

8:30AM-10:30AM: Abstract Number: 1558

Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].